Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink(University Medical Center Groningen), Elvino Barros, Robert D. Toto(Southwestern Medical Center), Anna Maria Langkilde(AstraZeneca (Sweden)), Dánae Duana Ávila(Universidad Autónoma del Estado de Hidalgo), Tom Greene(University Medical Center Groningen), Niels Jongs(University Medical Center Groningen), A Marañón, Fan Fan Hou(Southern Medical University), John J.V. McMurray(University of Glasgow), César A. Arias(Houston Methodist), Glenn M. Chertow(Stanford Health Care), Rafaël Maldonado(FIND), Juan Oddino(University of Glasgow), C. David Sjöström(University Medical Center Groningen), Natalia Cluigt, Raisa Kurlyandskaya(AstraZeneca (Poland)), Mikhail Kosiborod(AstraZeneca (Brazil)), Ricardo Correa‐Rotter(University Medical Center Groningen), Leonardo Sivak, A Alvarisqueta, Carolina Lúquez, David C. Wheeler(University College London), Cesar Javier Zaidman, Bergur V. Stefánsson(University Medical Center Groningen), Peter Rossing(Steno Diabetes Centers), Lília Nigro Maia(Faculdade de Medicina de São José do Rio Preto), Dov Aizenberg, M. Maurich, Pablo Ramallo, Juan Carlos Santos, Nicole Garcia, Pablo Raffaele, L.E. Gaite(The George Institute for Global Health), Ruben Garcia Duran, S. Solís, J. Bittar(University of Glasgow), M. Mayer(Sorbonne Université), A. Wassermann, Laura Maffei
European Heart Journal
February 9, 2021
Cited by 122


Related Papers